Last updated: March 26, 2024
Sponsor: University of Ulm
Overall Status: Active - Recruiting
Phase
N/A
Condition
Metabolic Disorders
Treatment
Oral glucose tolerance test with double-tracer dilution and intranasal placebo spray
Oral glucose tolerance test with double-tracer dilution and intranasal insulin spray
Clinical Study ID
NCT06295640
300/2022
Ages 18-30 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- BMI < 24 kg/m2
- no known primary diseases
- no hormonal contraception
Exclusion
Exclusion Criteria:
- Alcohol or drug abuse
- Smoking
- At screening: Hb < 12 g/dl for women and Hb < 14 g/dl for men
- Any (clinical) condition that would endanger participant's safety or questionscientific success according to a physician's opinion.
Study Design
Total Participants: 30
Treatment Group(s): 2
Primary Treatment: Oral glucose tolerance test with double-tracer dilution and intranasal placebo spray
Phase:
Study Start date:
March 18, 2024
Estimated Completion Date:
January 31, 2026
Study Description
Connect with a study center
Universityhospital Ulm
Ulm, 89081
GermanyActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.